Edition:
United States

Pain Therapeutics Inc (PTIE.OQ)

PTIE.OQ on NASDAQ Stock Exchange Global Select Market

10.19USD
25 May 2018
Change (% chg)

$0.53 (+5.49%)
Prev Close
$9.66
Open
$9.66
Day's High
$10.28
Day's Low
$9.66
Volume
14,952
Avg. Vol
17,257
52-wk High
$12.80
52-wk Low
$3.10

Chart for

About

Pain Therapeutics, Inc. is a biopharmaceutical company. The Company is focused on drug development efforts on disorders of the nervous system, such as chronic pain. The Company's lead drug candidate, REMOXY, is an abuse-deterrent, oral formulation of oxycodone (CII). The Company's other products is FENROCK. REMOXY is a... (more)

Overall

Beta: 2.72
Market Cap(Mil.): $70.27
Shares Outstanding(Mil.): 6.90
Dividend: --
Yield (%): --

Financials

  PTIE.OQ Industry Sector
P/E (TTM): -- 238.69 33.30
EPS (TTM): -1.73 -- --
ROI: -83.85 -7.54 13.04
ROE: -83.85 -10.33 14.90

BRIEF-Pain Therapeutics Q1 Loss Per Share $0.33

* PAIN THERAPEUTICS REPORTS FIRST QUARTER 2018 FINANCIAL RESULTS AND PROVIDES CORPORATE UPDATE ON REMOXY® ER

May 09 2018

BRIEF-Pain Therapeutics Announces FDA Advisory Committee Meeting For Remoxy ER

* PAIN THERAPEUTICS ANNOUNCES FDA ADVISORY COMMITTEE MEETING FOR REMOXY ER®

Mar 19 2018

BRIEF-FDA Accepts Remoxy NDA For Review, Sets PDUFA Date Of Aug 7, 2018

* FDA ACCEPTS REMOXY® NDA FOR REVIEW, SETS PDUFA DATE OF AUGUST 7, 2018

Mar 01 2018

BRIEF-Pain Therapeutics Resubmits New Drug Application For Remoxy ER

* PAIN THERAPEUTICS RESUBMITS NEW DRUG APPLICATION FOR REMOXY® ER, AN ABUSE-DETERRENT, EXTENDED-RELEASE DRUG CANDIDATE FOR THE TREATMENT OF CHRONIC PAIN

Feb 13 2018

BRIEF-Pain Therapeutics Signs On Demand Sales Agreement With JonesTrading Institutional Services

* PAIN THERAPEUTICS SAYS ON FEB 8, CO ENTERED INTO AN ATM CAPITAL ON DEMAND SALES AGREEMENT WITH JONESTRADING INSTITUTIONAL SERVICES LLC - SEC FILING

Feb 09 2018

BRIEF-Pain Therapeutics Inc QTRLY ‍Net Loss Per Share $0.37​

* PAIN THERAPEUTICS INC QTRLY ‍NET LOSS PER SHARE $0.37​ Source text: [http://bit.ly/2nGTz7J] Further company coverage:

Feb 05 2018

BRIEF-Pain Therapeutics Reports Positive Results From Nasal Abuse Potential Study With Remoxy

* PAIN THERAPEUTICS REPORTS POSITIVE TOP-LINE RESULTS FROM NASAL ABUSE POTENTIAL STUDY WITH REMOXY™

Jan 09 2018

BRIEF-Pain Therapeutics Reports Positive Regulatory Meeting For Remoxy

* PAIN THERAPEUTICS REPORTS POSITIVE REGULATORY MEETING FOR REMOXY™

Dec 18 2017

Competitors

Earnings vs. Estimates